Incretin Atlas › Trials › SUSTAIN-6
SUSTAIN-6
Semaglutide · T2D at high CV risk
Design
- Molecule(s)
- Semaglutide
- Population
- T2D at high CV risk
- Official title
- Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes
- Sponsor
- Novo Nordisk A/S
- Phase
- Phase 3
- Registry status
- completed · 2013-02 → 2016-03
- Participants
- 3297
- Registry
- NCT01720446
Cardiovascular and kidney outcomes
SUSTAIN-6 semaglutide 0.5/1.0 mg vs placebo · T2D at high CV risk · n = 3297 · 2016 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| 3-point MACE primary First occurrence of CV death, nonfatal MI (including silent), or nonfatal stroke | 0.74 | 0.58–0.95 | 108 vs 146 | verified |
| Cardiovascular death Death from cardiovascular causes | 0.98 | 0.65–1.48 | 44 vs 46 | verified |
| All-cause death Death from any cause | 1.05 | 0.74–1.50 | 62 vs 60 | verified |
| Myocardial infarction Nonfatal myocardial infarction only (fatal MI not reported separately) | 0.74 | 0.51–1.08 | 47 vs 64 | verified |
| Stroke Nonfatal stroke only (fatal stroke not reported separately) | 0.61 | 0.38–0.99 | 27 vs 44 | verified |
| Hospitalisation for heart failure Hospitalization for heart failure | 1.11 | 0.77–1.61 | 59 vs 54 | verified |
| Kidney composite New or worsening nephropathy: persistent macroalbuminuria, persistent doubling of serum creatinine with creatinine clearance <45 ml/min/1.73 m2 (MDRD), or need | 0.64 | 0.46–0.88 | 62 vs 100 | verified |
| Expanded MACE (MACE + HF hosp. + revasc. + UA) Expanded composite: death from CV causes, nonfatal MI, nonfatal stroke, revascularization (coronary or peripheral), and hospitalization for unstable angina or heart failure | 0.74 | 0.62–0.89 | 199 vs 264 | verified |
| Retinopathy complications Diabetic retinopathy complications: vitreous hemorrhage, onset of diabetes-related blindness, or need for treatment with an intravitreal agent or retinal photocoagulation | 1.76 | 1.11–2.78 | 50 vs 29 | verified |
| Coronary revascularisation Revascularization (coronary or peripheral; not coronary-only) | 0.65 | 0.50–0.86 | 83 vs 126 | verified |
| Hospitalisation for unstable angina Hospitalization for unstable angina pectoris | 0.82 | 0.47–1.44 | 22 vs 27 | verified |
Verbatim quotes (11)
- 3-point MACE · Results, Cardiovascular Outcomes, paragraph 1; Table 2
The composite primary outcome occurred in 108 of 1648 patients (6.6%) in the semaglutide group and 146 of 1649 (8.9%) in the placebo group (hazard ratio, 0.74; 95% confidence interval [CI], 0.58 to 0.95
- Cardiovascular death · Results, Cardiovascular Outcomes, paragraph 1; Table 2
deaths reported in 44 patients (2.7%) in the semaglutide group and 46 (2.8%) in the placebo group (hazard ratio, 0.98; 95% CI, 0.65 to 1.48; P = 0.92)
- All-cause death · Table 2
From any cause 62 (3.8) 1.82 60 (3.6) 1.76 1.05 (0.74–1.50) 0.79
- Myocardial infarction · Results, Cardiovascular Outcomes, paragraph 1; Table 2
Nonfatal myocardial infarction occurred in 47 patients (2.9%) in the semaglutide group and 64 (3.9%) in the placebo group (hazard ratio, 0.74; 95% CI, 0.51 to 1.08; P = 0.12)
- Stroke · Results, Cardiovascular Outcomes, paragraph 1; Table 2
Nonfatal stroke occurred in 27 patients (1.6%) in the semaglutide group and 44 (2.7%) in the placebo group (hazard ratio, 0.61; 95% CI, 0.38 to 0.99; P = 0.04)
- Hospitalisation for heart failure · Table 2
Hospitalization for heart failure 59 (3.6) 1.76 54 (3.3) 1.61 1.11 (0.77–1.61) 0.57
- Kidney composite · Results, Microvascular Outcomes; Table 2
New or worsening nephropathy occurred in 62 patients (3.8%) in the semaglutide group and 100 (6.1%) in the placebo group (hazard ratio, 0.64; 95% CI, 0.46 to 0.88; P = 0.005)
- Expanded MACE (MACE + HF hosp. + revasc. + UA) · Table 2
Expanded composite outcome‡ 199 (12.1) 6.17 264 (16.0) 8.36 0.74 (0.62–0.89)
- Retinopathy complications · Table 2
Retinopathy complications§ 50 (3.0) 1.49 29 (1.8) 0.86 1.76 (1.11–2.78)
- Coronary revascularisation · Table 2
Revascularization 83 (5.0) 2.50 126 (7.6) 3.85 0.65 (0.50–0.86)
- Hospitalisation for unstable angina · Table 2
Hospitalization for unstable angina pectoris 22 (1.3) 0.65 27 (1.6) 0.80 0.82 (0.47–1.44)
Primary sources
How to cite this page
Medical Adviser's Group. Incretin Atlas: SUSTAIN-6. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/sustain-6/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.